A hematopoietic cell (CFU-B1) capable of producing blast cell containing colonies in vitro was detected using a semisolid culture system. The CFU-B1 has the capacity for self-renewal and commitment to a number of hematopoietic lineages. Monoclonal antibody to the human progenitor cell antigen-i (HPCA-1) and a monoclonal antibody against the major histocompatibility class II antigen (HLA-DR) were used with fluorescence activated cell sorting to phenotype the CFU-B1. The CFU-B1 was found to express MylO but not HLA-DR antigen; experiments using complement-dependent cytotoxicity to eliminate DR positive cells confirmed this finding. Pretreatment of marrow cells with two chemotherapeutic agents, 5-fluorouracil and 4-hydroperoxycyclophosphamide facilitated detection of CFU-B1 derived colonies, while diminishing or totally inhibiting colony formation by other hematopoietic progenitor cells. CFU-Bl-derived colony formation was dependent upon the addition of exogenous hematopoietic growth factors. Media conditioned either by the human bladder carcinoma cell line 5637 or lectin stimulated leukocytes, as well as recombinant granulocyte-macrophage colony stimulating factor, interleukin 3 or interleukin la promoted blast cell colony formation. By contrast, neither recombinant erythropoietin, recombinant interleukin 4, purified macrophage colony stimulating factor or recombinant granulocyte colony-stimulating factor alone promoted blast cell colony formation.
Introduction
Primitive hematopoietic progenitor cells capable in vitro of producing colonies composed of blast cells (CFU-B 1)1 have 1. Abbreviations used in this paper: BFU-E, erythroid burst forming unit; CFU-B 1, blast cell colony forming unit; CFU-GM, granulocytemonocyte colony forming unit; CFU-GEMM, granulocyte, erythroid, monocyte, megakaryocyte colony forming unit; CFU-MK, megakaryocyte colony forming unit; CM, conditioned media; CSA, colony stimulating activity; CSF, colony stimulating factor, CSF-l (M-CSF), macrophage colony stimulating factor; Epo, erythropoietin; FBS, fetal bovine serum; 5-FU, 5 fluorouracil; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating factor; H-l, hemopoietin-1; 4-HC, 4 hydroperoxycyclophosphamide; IL-la, interleukin la; IL-3, interleukin 3 or multi-colony stimulating been detected in murine bone marrow, human umbilical cord blood and, most recently, in normal human marrow (1) (2) (3) (4) (5) (6) . These cells possess many of the features of stem cells in that they are capable of self-renewal and also commitment to a number of hematopoietic lineages (1) (2) (3) (4) (5) (6) .
Human marrow is composed of heterogeneous populations of hematopoietic precursor and progenitor cells. A variety of in vitro clonal assay systems have been utilized to detect progenitor cells in the presence of various hematopoietic growth factors (7) (8) (9) . Each of these cells have been shown to produce colonies composed of differentiated cellular elements with limited self-renewal capacity (10) (11) (12) . Since the frequency ofvarious hematopoietic progenitor cells appears to be directly related to the degree oftheir cellular differentiation, one would hypothesize that the frequency in normal bone marrow of CFU-B1 is extremely low. To facilitate the enrichment of CFU-B 1, a number of physical and immunological characteristics ofthese cells could be utilized (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Another means of obtaining enriched populations of CFU-BI might be to pharmacologically purge the marrow of more differentiated elements by in vitro exposure to chemotherapeutic agents (29, 30) . Van Zant has previously shown that in vitro exposure of murine marrow cells to 5-fluorouracil (5-FU) results in the direct, rapid kill of more differentiated progenitor cells and the selective sparing of primitive pluripotent hematopoietic stem cells (30) . 5-FU does not require in vivo metabolism for this effect to occur. We used monoclonal antibody labeling and fluorescence activated sorting or counterflow centrifugal elutriation and in vitro chemoselection to obtain a cell population with which we have developed an assay for the human CFUJ-B 1. These studies provide additional information on the chemosensitivity, immunological phenotype and growth factor dependence ofthe human CFU-B 1. These data suggest that the CFU-B1 is an extremely rare, quiescent cell present in human bone marrow. Data presented here also demonstrate the ability ofthe CFU-BI to form blast cell containing colonies in vitro in the presence of a number of hematopoietic regulatory molecules.
passed through a 150-MM screen and layered over an equal volume of Ficoll-Paque (specific gravity 1.077 g/cm'; Pharmacia Fine Chemicals, Piscataway, NJ). Density centrifugation was performed using a centrifuge (model TJ-6R; Beckman Instruments, Inc., Palo Alto, CA) at 500 g for 25 min at 4VC and the interface layer oflow density mononuclear cells (LD) was collected, washed, and resuspended in PBS-EDTA (PBS, pH 7.4 containing 5% FBS, vol/vol 0.01% ETDA, wt/vol, and 1.0 g/liter D-glucose). The cells were then injected into an elutriator system with a standard separation chamber (Beckman Instruments, Inc.) that had previously been sterilized with a 70% ethanol solution, washed with sterile distilled water, and primed with PBS-EDTA. Rotor speed and temperature were maintained at 1,950 rpm and 100C throughout the elutriation. After loading, 200 ml of effluent was collected at a flow rate of 10 ml/min and 100 ml were collected at flow rates of 11, 12, 14, 16, 18, 20, 22, 24, 28 , and 32 ml/min, after which the rotor was stopped and the final fraction flushed from the separation chamber (3 1).
Treatment with chemotherapeutic agents. Preparation of phytohemagglutinin stimulated leukocyte conditioned medium. Peripheral blood collected from hematologically normal volunteers was diluted 1:1 with IMDM containing 20 U/ml sodium heparin and layered over an equal volume ofFicoll-Paque. Density centrifugation was performed as previously described and the interface layer oflow density mononuclear cells collected, washed, and suspended in IMDM with 10% FBS at 1 X 106 cells/ml. 1% vol/vol phytohemagglutinin (Wellcome Diagnostics, Dartford, England) was added and the cell suspension incubated for 7 d at 37°C with 5% CO2 in 100% humidified air. The cell suspension was then pelleted at 500 g and the supernatant stored at -20°C.
Source ofgrowth factors. Lyophilized, partially purified (57 U/mg protein) human urinary erythropoietin (Epo) (Toyobo Co., Ltd., Osaka, Japan) was reconstituted in IMDM and stored at 20 U/ml at -20°C. Purified human macrophage colony stimulating factor (CSF-1) with a specific activity of I0O U/mg protein was a gift of Dr. Peter Ralph of the Cetus Corporation, Emeryville, CA. Recombinant human granulocyte colony-stimulating factor (G-CSF) with a specific activity of 1 X 101 U/mg and recombinant human erythropoietin (rEpo, 70,000-80,000 U/mg protein > 95% purity by SDS-PAGE and HPLC) were purchased from AmGen Biologicals, Thousand Oaks, CA, while the recombinant human interleukin 3 (rIL-3, specific activity 108 CFU/mg protein), interleukin 4 (rIL-4, specific activity 108 CFU/mg protein) and human granulocyte-macrophage colony-stimulating factor (rGM-CSF, specific activity greater than 5 X 107 CFU c/mg protein) were purchased from the Genzyme Corp., Boston, MA. The recombinant human interleukin la (rIL-la) was obtained from two sources. One preparation of rIL-la was a gift of Dr. Peter LoMedico, Hoffman-LaRoche, Nutley, NJ, and had a specific activity of 109 U/mg protein, while the second source of rIL-Ia was the Genzyme Corp., Boston, MA, and had a specific activity of 108 U/mg protein.
Hematopoietic progenitor cell assays. 1 X 10' drug-treated or control cells were suspended in 35-mm plastic tissue culture dishes (Costar, Cambridge, MA) containing a 1-ml mixture of IMDM, 1.1% methylcellulose, 30% FBS, 5 X 10-' M 2-mercaptoethanol, 1 U Epo, and 10% PHA-LCM (32) . The culture dishes were incubated at 370C in a 100% humidified atmosphere of 5% CO2 in air. Granulocyte-macrophage derived colonies (CFU-GM), erythropoietic bursts (BFU-E) and multiple lineage colonies (CFU-GEMM) were enumerated after 14 and 21 d using an inverted light microscope using standard criteria for their identification ( 12, 32) .
CFU-BJ assay. 1 X 105 drug-treated or control cells were suspended in 35 mm plastic tissue culture dishes containing a 1-ml mixture of IMDM, 1.1% methylcellulose, 30% FBS, 5 X 10-5 M 2-mercaptoethanol, 1 U of Epo, and 10% 5637 CM. The culture dishes were incubated at 370C in a 100% humidified atmosphere of 5% CO2 in air and at 21 d scanned using an inverted light microscope to detect blast cell colonies.
Colonies composed of undifferentiated cellular elements were plucked from the methylcellulose under direct microscopic visualization using sterile 100-Ml glass micropipettes (Drummond Scientific Co., Broomall, PA) and suspended in 200 ,ul IMDM in sterile 1.5-ml microcentrifuge tubes (Tekmar Co., Cincinnati, OH). 100 ;l of this volume was suspended in a 350-Ml mixture of IMDM with 1.1% methylcellulose, 30% FBS, 5 X 10-' M 2-mercaptoethanol, 0.35 U Epo, and 10% 5637 CM or PHA-LCM in 24-well tissue culture plates (Corning Glass Works). The remaining 100 gl was transferred to slides on a Cytospin 2 (Shandon Southern Instruments, Inc., Sewickly, PA) at 750 rpm for 5 min for Wright Giemsa staining and microscopic examination. Culture plates were incubated at 370C in 100% humidified air with 5% CO2 for 14 d, after which they were plucked from the methylcellulose, resuspended in 100 Ml PBS, and transferred to slides for staining and examination.
Separation ofcells by cell sorting
The LD marrow cells were depleted of adherent cells by methods previously described (33 * Marrow cells or marrow cell fractions were assayed in the presence of 1.0 U/ml of a partially purified preparation of human urinary erythropoietin (57 U/mg protein, Toyobo Co., Ltd., Osaka, Japan), and 10% phytohemagglutinin stimulated leukocyte conditioned media. $ Low density marrow cells were injected into a Beckman elutriator system with a standard separation chamber (Beckman Instruments, Inc.). After loading, the flow rate of buffer was maintained at 10 ml/ min with a rotor speed of 1,950 rpm and 200 ml of effluent was collected. The flow rate was increased in 2-ml/min increments and 100 ml of effluent was collected at each increment until a flow rate of 32 ml/min was achieved. The cells in each fraction were then assayed for colony formation. 1Colonies were enumerated after 14 d of incubation. Colonies were enumerated after 21 d of incubation. Each point represents the mean± 1 SD of duplicate points.
ing PE conjugated IgG2, myeloma protein to the cells, and the nonspecific background fluorescence was less than 1% at the gate settings used to determine positive DR/PE staining. Cells were maintained at 4VC before and during cell sorting. Cell sorting. Cells were sorted on a Coulter Epics 753 dye laser flow cytometry system (Coulter Electronics, Hialeah, FL). The methods employed have been previously described (28) . All data was collected on a 256 channel three decade log scale. TR was excited by the 590-nm line emitted from a coherent dye laser pumping rhodamine 6G dye, which was in turn excited by the 488 nm dye from a dedicated 6 W argon laser. The FITC and PE were excited using the 488-nm wavelength from a second 6 W argon laser. Sorting windows were established for three separate parameters: forward light scatter, TR or FITC fluorescence, and PE fluorescence by first selecting (gating) for high density MylO positive cells as previously described (28) and then setting sort gates for low and undetectable densities of MHC class II antigen. After sorting, the recovered cell populations were washed twice and resuspended in media containing 10% FCS (Hyclone, Logan UT). The purity of sorted cells was determined by reanalyzing aliquots of the sorted subsets on the Coulter Epics 753 immediately after the sort was finished (28) Complement-dependent cytotoxicity. FR 12-14 cells were first incubated at 4VC and at a concentration of 6 X 106/ml in 50 zd IMDM for 45 min with an equal volume of IMDM and anti-HLA-DR antibody (Becton Dickinson) at a plateau killing concentration in sterile microcentrifuge tubes. Control cells were incubated in a similar fashion with media alone, antibody alone or complement alone. The tubes were then centrifuged at 500 g for 3 min, the supernate was removed, and the cells resuspended in 100 jul solution containing 20% rabbit complement, and incubated at 370C for 60 min. Cells were next washed thrice in IMDM and assayed for progenitor cell and blast cell derived colonies as previously described. The number of cells plated was determined by cell counts made before treatment with antibody and complement.
Statistical analysis. All results are presented as the mean± 1 SD or SEM. Levels of significance for comparison between samples were determined using the t test distribution.
Results
To obtain populations of marrow cells enriched for primitive hematopoietic progenitors, fractions of LD marrow cells were obtained by counterflow centrifugal elutriation. The ability of each fraction to form CFU-GEMM derived colonies was used preliminarily as an indicator of the presence of primitive progenitor cells. The fraction eluting at a flow rate of 12-14 ml/ min constituted 10.2±1.6% of LD marrow and provided a 5-fold enrichment for CFU-GEMM derived colonies enumer- (Fig. 1 a) . The cells in these colonies were predominantly agranular blasts with basophilic cytoplasm and multiple, large nucleoli ( Fig. 1 b) that demonstrated neither specific nor nonspecific esterase activity; between 28 and 90% ofthese colonies were composed of such cells. Monocytes, promyelocytes, and segmented neutrophils frequently represented minority populations in the colonies, which varied in size from 62 to 2,101 cells per one-half colony (Table III) .
We detected few CFU-B1 derived colonies when non-drug treated FR12-14 cells were assayed (Table IV) . This was due presumably to the prolific growth of more differentiated progenitor cells that potentially obscured the detection ofCFU-BI derived colonies and the relative rarity of the CFU-B1. By contrast, CFU-B 1 -derived colonies were repeatedly observed when FR 12-14 cells were exposed to 5-FU or 4-HC before plating (Table IV) . A greater number of CFU-B1 were observed when 5-FU-treated cells were assayed than when 4-HC-treated cells were assayed for CFU-B1 derived colony formation (P < 0.01).
CFU-B1-derived colony formation was dependent on the presence of 5637 CM. No blast cell-containing colonies were detected in the absence ofCM, while the addition of Epo alone or in the presence of 5637 CM did not enhance colony formation (Table V) . Secondary colonies derived from one-half of the CFU-Bl colonies were individually transferred to slides, stained and examined at day 14. The CFU-B1-derived colonies were able to form single-and multilineage colonies composed of virtually every hematopoietic cellular type. In addition, roughly 20% of these primary colonies gave rise to secondary blast cell colonies after replating (Tables VI, X) . Other colony types, notably those of monocyte-macrophage lineage, infrequently retained a limited replating ability. In such cases, secondary colony formation was always restricted to the single lineage product(s) of the primary colony; none of these colo- nies were able to produce multilineage or blast secondary colonies after 21 d in culture. 5-FU-treated FR 12-14 cells were also plated in the presence of a variety of purified or recombinant growth factors (Table VII) . rG.M-CSF, rIL-3, and rIL-la were each capable alone ofpromoting CFU-B 1-derived colony formation. In contrast, neither CSF-1, rG-CSF, rIL-4, nor rEpo promoted blast cell colony formation.
To immhunologically phenotype the CFU-Bl, NALT but that the CFU-Bl is different from the other hematopoietic progenitor cells assayed in that it is HLA-DR-. It is also important to note a marked enrichment for CFU-Bl that has been achieved with cell sorting. In these studies 0.2% of the MylO.../DR-were CFU-B1, which represents a 100-fold enrichment over that achieved with density centrifugation and counterflow centrifugal elutriation coupled with drug treatment. Complement-dependent cytotoxicity was utilized as an alternate methodology to eliminate HLA-DR positive cells in elutriated marrow. This process greatly diminished colony formation by CFU-GM, BFU-E, and CFU-GEMM but not CFU-Bl (Table IX) .
A linear response relationship between the number of My10"+DR-cells plated and blast cell colonies enumerated was observed when 5 X 102 to 2 X 103 cells/ml were assayed (Fig. 3) . At higher cell densities, the ability to detect and isolate CFU-B 1-derived colonies among other hematopoietic types was obscured and possibly accounts for the plateau levels reached. When 102 cells/ml were plated, a few (mean = 2.8) monocyte-macrophage but no CFU-B1 derived colonies were observed.
Analysis of antibody/fluorochrome stained NALT-cells from multiple donors indicated the presence of a subpopulation of 2-4% MylI0"DR-cells. When FR 12-14 cells were identically prepared for sorting, 5-14% were found to be My10+++DR-, demonstrating a higher frequency of this immunological phenotype in the elutriated marrow.
MylO`+DR-cells from either source generated blast cell colonies in vitro.
To be certain that the blast cell colonies assayed from Myl0+++DR-marrow cells had similar behavior to those colonies that were detected after 5-FU treatment, their dependence on the addition of hematopoietic growth factors (Table X) , their colony size and morphology (Table XI) , and their capacity to form secondary colonies (Table XII) 5637 CM and erythropoietin appears to be identical to that ofblast cell colonies cloned from 5-FU treated marrow. Blast colonies were able to form secondary blast cell colonies and also multilineage and single lineage progenitor cell-derived colonies.
Discussion
An in vitro assay system with which to examine the biological characteristics of human pluripotent hematopoietic stem cells that have a capacity for self-renewal and to differentiate along multiple cellular lines has been a long-term goal of a number of groups working in the field of hematopoiesis. Recently, a great deal ofprogress has been achieved toward accomplishing this objective. Initially, Nakahata and Ogawa described such an assay system using human umbilical cord blood as a source of cells (3) . More recently, Rowley and co-workers (4), Leary and Ogawa (5), and Gordon and co-workers (6) have each 11.0 U/ml of recombinant erythropoietin with a specific activity of 70,000-80,000 U/mg (AmGen Biologicals). "100 U/ml of recombinant granulocyte colony stimulating factor with a specific activity of 1 X 108 U/mg. 100 U/ml of recombinant human granulocyte-macrophage colony stimulating factor with a specific activity of 5 X I0' CFU-GM/mg protein (Genzyme Corp., Boston, MA). ** 300 U/ml of recombinant human interleukin 3 with a specific activity of 108 CFU-GEMM/mg protein.
# 50 U/ml recombinant human interleukin I a with a specific activity of 109 U/mg protein (gift of Dr. Peter LoMedico, Hoffiman-LaRoche, Nutley, NJ) or recombinant interleukin I a with a specific activity of 101 U/mg protein.
* 100 U/ml of recombinant human interleukin 4 with a specific activity of 108 proliferation units of human tonsillar B cells/mg protein.
described systems with which to detect these primitive hematopoietic progenitor cells in human marrow. In the present report, we have concentrated on determining the sensitivity of these cells to chemotherapeutic agents, analyzing the immunological phenotype of the CFU-B1, and further defining the dependence of these cells on hematopoietic regulatory molecules.
A number of groups have demonstrated that a population of primitive hematopoietic stem cells is capable of surviving either in vitro or in vivo exposure to chemotherapeutic agents such as 5-FU, 4-HC, and hydroxyurea (29, 30, 34, 35) . This chemoselection was successfully exploited in the present studies in order to eliminate overgrowth of colonies derived from more differentiated progenitor cells. The apparent scarcity of CFU-B1-derived colonies in non-drug-treated FR 12-14 should not be interpreted as a reflection ofthe absence ofthese cells from these fractions, but rather to their relative rarity and to the difficulty of isolating CFU-Bl derived colonies among other hematopoietic colonies present in the culture dish. The detection of CFU-Bl in a MylI0" population of cells that are not drug treated confirms the finding of Leary and Ogawa (5) that the CFU-BI is MylO positive and emphasizes the importance of using enriched marrow populations with which to assay for CFU-B1. The rarity of these cells in human marrow necessitates the use of either cell sorting, panning, or purging of more differentiated progenitors if one is to detect the CFU-B1 using presently available in vitro assay systems.
It is important to note that drug treatment of cells was exploited to facilitate the detection of CFU-B1 by preferentially killing more committed progenitors. It cannot be assumed that all or even a majority of CFU-B1 survive treatment; the enrichment effected by 5-FU or 4-HC exposure is merely operational and can not be used to quantitate the CFU-Bl in marrow.
The survival of CFU-B1 after 4-HC treatment has clinical importance. 4-HC has been used to purge marrows of neoplastic cells prior to autologous transplantation for acute nonlymphocytic, leukemia (36) . Such 4-HC purged marrow following transplantation is capable ofengraftment and initiation of sustained hematopoiesis. Since the CFU-B I appears not to be affected by 4-HC it is possible that this cell or some closely related cell is responsible for marrow engraftment following such transplants. In support ofthis hypothesis, Siena et al. (37) and Winton and Colenda (38) have shown that 4-HC is extremely toxic to CFU-GEMM and BFU-E yet is capable of initiating in vitro long-term hematopoiesis, suggesting that the cells surviving 4-HC are responsible for marrow repopulation. BFU-E and CFU-GEMM have not proven to be suitable for predicting stem cell survival after 4-HC treatment in vitro (37) , while the logarithm of the CFU-GM content of treated grafts has recently been shown to be linearly correlated with time to recovery of peripheral leukocyte counts following autologous transplantation. The data presented in this report suggest that the CFU-BI assay might also be useful for this purpose. The resistance of CFU-Bl to 4-HC is in agreement with published reports by two other groups (4, 39, 40). Information has been presented demonstrating that the majority of normal human bone marrow CFU-GM, BFU-E and CFU-GEMM express determinants recognized by both HLA-DR and MylO antibodies (14, 15, 28) . By using combinations of HLA-DR and MylO antibodies and tWo-color fluorescence activated cell sorting for isolation of hematopoietic progenitor cells differing in the density expression of HLA-DR and MylO antigens, it has been possible to highly enrich for these cells with some fractions having a total cloning efficiency for CFU-GM, BFU-E, and CFU-GEMM of up to 47% (28) . We have used similar methodology to obtain enriched populations of CFU-B1. The sible for sustaining long-term hematopoiesis in vitro and that responsible for generating blast cell colonies in vitro might be closely related. The My10...DR-population of cells could be cultured at 5 X 102 to 2 X 103 cells/ml while maintaining qualitatively normal colony growth and linear replating characteristics. At higher cellular densities, total colonies overlapped and were difficult to accurately isolate; when these cells were plated at 102/ml, blast cell colony growth was nondetectable. Similar linear responses at low plating concentrations of highly purified fetal hematopoietic progenitors has been described by Emerson and co-workers (23) when assaying for other hematopoietic colony types.
A large amount of information has been accumulated to show that the process of blood formation is sustained throughout life by a number of hematopoietic growth factors, collectively known as colony-stimulating factors (CSFs) (7) (8) (9) . The availability of the human CFU-B1 assay has allowed us to determine its dependence on the addition ofexogenous growth factors. Our findings suggest that even these primitive hematopoietic stem cells are in vitro dependent on the addition of exogenous CSFs. No CFU-B 1 were assayable in the absence of conditioned media or purified hematopoietic regulatory molecules. CFU-B1-derived colony formation was observed after the addition of 5637 CM to the culture mixture. This particular cell line is known to constitutively produce CSAs for myeloid and multipotential progenitors, while H-1, GM-CSF, and G-CSF have each been purified from the conditioned media ofthis cell line (44, 45). Addition ofEpo to 5637 did not further favor CFU-B1 derived colony formation (Table V) . This information emphasizes the distinct differences between the CFU-B I and CFU-GEMM (12, 32) . Four relatively lineage specific factors, rG-CSF, rEpo, rIL-4, and purified CSF-1 did not promote CFU-B1 derived colony formation at any concentration, suggesting that the ability of hematopoietic cells to respond to such factors is acquired at a much more distant step along the differentiation pathway than that at which the CFU-B1 resides.
Hemopoietin-1 (H-1), previously termed synergistic factor, was first detected by its ability to induce stem cells to become responsive to other hematopoietic growth factors (46) (47) (48) . H-l has been shown to be identical to interleukin la (47, 48) . It has recently been reported that H-I activity as identified by an in vitro assay ofthe ability of 5637 CM to promote high proliferative capacity colony formation can be completely neutralized by an antibody to IL-Ia (47, 50) . In the original description of the biological properties of H-1 by Stanley and co-workers, the addition of this growth factor alone did not lead to the appearance of hematopoietic colonies, but acted synergistically with CSF-l or IL-3 (46, 49) . The promotion of CFU-Bl derived colony formation by rIL-I a alone by 5-FU treated marrow but not by Myl0+++DR-is at first confusing since the blast cell colonies generated from either cellular source had identical biological characteristics. An explanation for this difference might be in the recent observation by a number of groups that IL-1 a acts by promoting the release ofcytokines from a variety of marrow accessory cells (51) (52) (53) (54) (55) (56) (57) . Since the 5FU-treated marrow fraction is a rather heterogenous population the IL-1 a Blast cell colonies were derived from assays of low density marrow cells that were further enriched for marrow cells by centrifugal elutriation. These cells were then sorted and the MylIO..DR-fraction plated in the presence of 5637 CM. After 21-25 d of incubation, the blast cell colonies were replated into cultures containing 5637 CM and incubated for an additional 14-16 d.
Blast cell; b macrophage; c granulocyte; d granulocyte-macrophage; granulocyte, erythroid, macrophage, megakaryocyte; f erythropoietic burst; ' granulocyte, erythroid, macrophage.
effect observed is presumably due to stimulated release of growth factor(s) from marrow auxiliary cells rather than an initial independent direct effect on the CFU-B1. These accessory cell cytokines then would promote CFU-Bl derived colony formation, perhaps in part by synergizing with IL-la. The inability to observe a similar phenomenon when assaying the MylO++DR-cells, then, would be due to an absence of its accessory cell population from this highly select cell population, thus depriving the cells ofthe accessory cell-derived cytokine necessary for blast cell colony formation. These data suggest that IL-la might have potential therapeutic use as a growth factor to promote marrow repopulation following chemotherapy or radiation therapy (58) .
The availability ofassays for more primitive human hematopoietic stem cells provides investigators with a new cell biological tool with which to investigate normal human blood cell formation. In addition, new information concerning bone marrow failure states and clonal hematopoietic neoplasms in man will likely to be forthcoming with the use of the CFU-BI assay.
